Using Bevacizumab before surgery for high-grade brain gliomas
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
NA · The First Affiliated Hospital of Zhengzhou University · NCT06747728
This study is testing if giving a drug called bevacizumab before surgery can help people with high-grade brain tumors have better outcomes.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Zhengzhou University (other) |
| Drugs / interventions | Bevacizumab |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT06747728 on ClinicalTrials.gov |
What this trial studies
This study evaluates the efficacy and safety of bevacizumab, an anti-angiogenic drug, as a preoperative treatment for patients diagnosed with new high-grade gliomas. Glioblastoma, a type of brain tumor, often recurs after surgery due to its infiltrative nature and reliance on blood vessel growth. By inhibiting vascular endothelial growth factor (VEGF), bevacizumab aims to reduce tumor blood supply, potentially improving surgical outcomes. The study will involve patients aged 18 and older with a confirmed diagnosis of high-grade glioma and a Karnofsky Performance Status (KPS) score of 60 or higher.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed imaging diagnosis of high-grade glioma and a KPS score of 60 or above.
Not a fit: Patients with prior treatment using anti-angiogenic drugs or those with serious comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve surgical outcomes and prolong survival for patients with high-grade gliomas.
How similar studies have performed: Previous studies have shown promise with anti-angiogenic therapies in glioblastoma, but this specific approach with bevacizumab in the preoperative setting is less commonly tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Male or female. * Imaging diagnosis of high-grade glioma. * KPS score ≥60. Exclusion Criteria: * Prior treatment with anti-angiogenic targeted drugs; * Comorbid serious cardiac, pulmonary, hepatic, or renal disease; * History of an arterial/venous thrombotic event within 6 months prior to screening; * Combination of infectious diseases such as tuberculosis and viral hepatitis; * Comorbid infectious diseases such as tuberculosis, viral hepatitis, uncontrolled high blood pressure, bleeding disorders, and long-standing unhealed wounds or incompletely healed fractures; * Patients with a history of psychotropic substance abuse that cannot be stopped or patients with mental disorders; * Abnormal coagulation function, with bleeding tendency * Patients who, in the opinion of the investigator, are not suitable for inclusion in the study (e.g., pregnant and lactating women).
Where this trial is running
Zhengzhou, Henan
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (RECRUITING)
Study contacts
- Principal investigator: Junkuan Wang, M.D. — The First Affiliated Hospital of Zhengzhou University
- Study coordinator: Junkuan Wang, M.D.
- Email: wjkuan@sina.cn
- Phone: 15036177557
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Brain Glioma